Development of Covalent Drugs with New Emerging Technologies

Covalent drugs could provide pharmacological advantages like prolonged duration of action and enhanced potency over non-covalent drugs. In recent years, their discovery has been boosted by rational design and facilitated by emergence of new technologies in proteomics. This enables drug identification with higher selectivity by identifying their binding site.

With their unique mechanistic properties that differentiate them from non-covalent inhibitors, covalent drugs can be administered at lower doses and frequencies reducing off-target events and increasing patients’ compliance. In addition, they can be an effective strategy for low vulnerability targets where high levels of occupancy are needed to generate the desired physiological outcomes. Covalent therapeutics can also be a strategy to overcome drug-resistance mutations in the gene encoding the target protein like in case of the epidermal growth factor receptor (EGFR).

Join this webinar to learn more about the new emerging technologies to develop covalent therapeutics.

Speaker

Simon Haydar, SVP & Head, Integrated Drug Discovery Solutions, Aragen Life Sciences

Simon Haydar comes with more than two decades of rich experience in leading integrated drug discovery projects. Over the years, he has spearheaded various discovery projects to develop novel oral therapies for different therapy areas. His functional expertise spans across areas such as discovery R&D leadership, licensing due diligence, biotech alliances & partnerships, external R&D activities and mergers and acquisitions.

Prior to joining Aragen, Simon has held various leadership roles at Syngene International Limited, Assembly Biosciences, Eli Lily, GSK and Pfizer.

Message Presenter